Novo Ventures-backed ReViral, a biotech company treating respiratory syncytial virus, has been acquired by Pfizer for USD 525m.
Novo Ventures-backed ReViral, a biotech company treating respiratory syncytial virus, has been acquired by Pfizer for USD 525m.